| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| ln Vivo |
2-iodoaniline (1.0 mM/kg, 1.25 mM/kg, 2.5 mL; intraperitoneal injection; single dose) shows possible hepatotoxicity and nephrotoxicity in male Fischer 344 rats [1].
In male Fischer 344 rats, intraperitoneal injection of 2-Iodobenzenamine hydrochloride salt at doses of 1.0 or 1.25 mmol/kg induced the following effects within 24 hours [1]: - Urine output was significantly decreased compared to pair-fed controls. At 1.0 mmol/kg, urine output on day 1 was 4 ± 1 mL/24 h (control: 12 ± 2 mL/24 h, p < 0.05); at 1.25 mmol/kg, urine output was 4 ± 1 mL/24 h (control: 9 ± 1 mL/24 h, p < 0.05) [1]. - Blood urea nitrogen (BUN) concentration was not significantly elevated. At 1.0 mmol/kg, BUN was 27.1 ± 8.2 mg/dL (control: 19.7 ± 2.2 mg/dL); at 1.25 mmol/kg, BUN was 25.0 ± 2.7 mg/dL (control: 18.0 ± 1.4 mg/dL). Differences were not statistically significant [1]. - Kidney weight (g/100 g body weight) was decreased at 1.0 mmol/kg: treated 0.32 ± 0.01 vs. control 0.37 ± 0.01 (p < 0.05). Absolute kidney weight was not significantly changed [1]. - Renal cortical slice accumulation of p-aminohippurate (PAH) was decreased under both basal and lactate-stimulated conditions at both doses (1.0 and 1.25 mmol/kg), as shown in Figures 1 and 2 [1]. - Renal cortical slice accumulation of tetraethylammonium (TEA) was not significantly affected by 2-Iodobenzenamine at 1.25 mmol/kg (Figure 3) [1]. - Plasma alanine aminotransferase (ALT/GPT) activity was significantly elevated at both doses (1.0 and 1.25 mmol/kg), indicating hepatotoxicity (Figure 4) [1]. - Histological examination of livers showed dose-dependent congestion, centrilobular degeneration, and the presence of reactive nuclei; these changes were localized and minor in nature [1]. |
|---|---|
| Animal Protocol |
Animal/Disease Models: Male Fischer 344 rat (185-260 g) [1]
Doses: 1.0 mM/kg, 1.25 mM/kg for 2.5 mL Route of Administration: intraperitoneal (ip) injection; single dose; monitor renal function and liver 24 hrs (hrs (hours)) after treatment Functional Experimental Results: Causes oliguria, diminished kidney weight, diminished tubular casts, and diminished accumulation of organic anions in renal cortical slices. Plasma ALT/GPT activity increases, and the morphology of the centrilobular region changes. Male Fischer 344 rats (185–260 g) were housed in metabolism cages. 2-Iodobenzenamine was administered as a hydrochloride salt dissolved in 0.9% saline. The compound was injected intraperitoneally (i.p.) at doses of 1.0 or 1.25 mmol/kg (injection volume 2.5 mL/kg). Control animals (pair-fed) received vehicle (0.9% saline, 2.5 mL/kg i.p.). Food was withheld between 09:00–13:00 h on the day of dosing to avoid food contamination of urine. Urine was collected on ice for 24 h post-treatment. At 24 h after injection, rats were anesthetized with diethyl ether, blood was collected from the abdominal aorta, and kidneys and livers were excised for analysis [1]. |
| Toxicity/Toxicokinetics |
2-Iodobenzenamine induced acute nephrotoxicity (oliguria, decreased kidney weight, reduced PAH accumulation) and hepatotoxicity (elevated ALT/GPT, centrilobular degeneration) in male Fischer 344 rats at intraperitoneal doses of 1.0 and 1.25 mmol/kg. BUN was not significantly elevated. Unlike other 2-haloanilines (2-fluoro, 2-chloro, 2-bromo), 2-Iodobenzenamine did not increase BUN concentration. The severity of toxicity was similar among all 2-haloanilines tested, and aniline was less toxic than its 2-halo derivatives. Histological changes in the kidney were minor, including interstitial perivascular edema and tubular casts. Bladder alterations included submucosal hemorrhage and slight edema [1].
|
| References | |
| Additional Infomation |
2-Iodobenzenamine (2-iodoaniline) is a halogenated aniline derivative. The study compared the acute renal and hepatic toxicity of 2-haloanilines (2-FA, 2-CIA, 2-BrA, 2-IA) with aniline in Fischer 344 rats. The results showed that halogen substitution at the 2-position of aniline increased hepatic and renal toxicity compared to aniline itself, but the nature of the halogen (fluoro, chloro, bromo, iodo) did not markedly influence the severity of toxicity. The mechanism of toxicity is unknown but may involve cytochrome P-450-mediated metabolism, as suggested by the centrilobular pattern of liver damage [1].
|
| Molecular Formula |
C6H6IN
|
|---|---|
| Molecular Weight |
219.03
|
| Exact Mass |
218.954
|
| CAS # |
615-43-0
|
| Related CAS # |
2-Iodoaniline-13C6;1261170-87-9
|
| PubChem CID |
11995
|
| Appearance |
White to light brown solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
262.0±23.0 °C at 760 mmHg
|
| Melting Point |
55-58 °C(lit.)
|
| Flash Point |
112.3±22.6 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.688
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
74.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=CC(=C1N)I
|
| InChi Key |
UBPDKIDWEADHPP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6IN/c7-5-3-1-2-4-6(5)8/h1-4H,8H2
|
| Chemical Name |
2-Iodoaniline
|
| Synonyms |
NSC-34544 NSC34544NSC 345442-Iodobenzenamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~456.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5656 mL | 22.8279 mL | 45.6558 mL | |
| 5 mM | 0.9131 mL | 4.5656 mL | 9.1312 mL | |
| 10 mM | 0.4566 mL | 2.2828 mL | 4.5656 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
